Trevena, Inc. (TRVN)
USD 1.27
(-0.78%)
USD 1.27
(-0.78%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 40.6 Million USD | -16.59% |
| 2022 | 48.68 Million USD | -39.24% |
| 2021 | 80.12 Million USD | -37.28% |
| 2020 | 127.73 Million USD | 171.82% |
| 2019 | 46.99 Million USD | -29.63% |
| 2018 | 66.77 Million USD | -8.17% |
| 2017 | 72.72 Million USD | -36.57% |
| 2016 | 114.65 Million USD | -34.62% |
| 2015 | 175.35 Million USD | 61.86% |
| 2014 | 108.33 Million USD | 155.56% |
| 2013 | 42.39 Million USD | 424.17% |
| 2012 | 8.08 Million USD | -58.33% |
| 2011 | 19.4 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 22.94 Million USD | -26.32% |
| 2024 Q1 | 31.13 Million USD | -23.32% |
| 2023 FY | 40.6 Million USD | -16.59% |
| 2023 Q3 | 45.13 Million USD | 16.15% |
| 2023 Q1 | 38.29 Million USD | -21.34% |
| 2023 Q2 | 38.85 Million USD | 1.48% |
| 2023 Q4 | 40.6 Million USD | -10.03% |
| 2022 Q3 | 51.01 Million USD | -21.27% |
| 2022 Q1 | 64.41 Million USD | -19.6% |
| 2022 Q4 | 48.68 Million USD | -4.58% |
| 2022 FY | 48.68 Million USD | -39.24% |
| 2022 Q2 | 64.8 Million USD | 0.6% |
| 2021 FY | 80.12 Million USD | -37.28% |
| 2021 Q4 | 80.12 Million USD | -12.57% |
| 2021 Q1 | 118.49 Million USD | -7.24% |
| 2021 Q3 | 91.64 Million USD | -18.32% |
| 2021 Q2 | 112.2 Million USD | -5.31% |
| 2020 Q3 | 122.56 Million USD | 84.8% |
| 2020 Q1 | 39.05 Million USD | -16.9% |
| 2020 Q2 | 66.32 Million USD | 69.84% |
| 2020 Q4 | 127.73 Million USD | 4.22% |
| 2020 FY | 127.73 Million USD | 171.82% |
| 2019 Q1 | 71.88 Million USD | 7.65% |
| 2019 FY | 46.99 Million USD | -29.63% |
| 2019 Q2 | 65.18 Million USD | -9.33% |
| 2019 Q3 | 56.77 Million USD | -12.91% |
| 2019 Q4 | 46.99 Million USD | -17.22% |
| 2018 Q3 | 76.11 Million USD | 5.23% |
| 2018 FY | 66.77 Million USD | -8.17% |
| 2018 Q4 | 66.77 Million USD | -12.26% |
| 2018 Q2 | 72.32 Million USD | 5.37% |
| 2018 Q1 | 68.64 Million USD | -5.61% |
| 2017 Q2 | 92 Million USD | -10.79% |
| 2017 Q1 | 103.14 Million USD | -10.04% |
| 2017 FY | 72.72 Million USD | -36.57% |
| 2017 Q4 | 72.72 Million USD | -13.67% |
| 2017 Q3 | 84.24 Million USD | -8.44% |
| 2016 Q2 | 148.57 Million USD | -10.98% |
| 2016 Q1 | 166.9 Million USD | -4.82% |
| 2016 FY | 114.65 Million USD | -34.62% |
| 2016 Q4 | 114.65 Million USD | -6.12% |
| 2016 Q3 | 122.13 Million USD | -17.8% |
| 2015 Q1 | 103.19 Million USD | -4.74% |
| 2015 FY | 175.35 Million USD | 61.86% |
| 2015 Q4 | 175.35 Million USD | 2.74% |
| 2015 Q3 | 170.67 Million USD | 58.05% |
| 2015 Q2 | 107.98 Million USD | 4.64% |
| 2014 Q4 | 108.33 Million USD | 46.49% |
| 2014 Q3 | 73.95 Million USD | -12.67% |
| 2014 Q1 | 95.15 Million USD | 124.46% |
| 2014 FY | 108.33 Million USD | 155.56% |
| 2014 Q2 | 84.68 Million USD | -11.0% |
| 2013 Q1 | - USD | -100.0% |
| 2013 FY | 42.39 Million USD | 424.17% |
| 2013 Q2 | 56.44 Million USD | 0.0% |
| 2013 Q4 | 42.39 Million USD | -15.97% |
| 2013 Q3 | 50.44 Million USD | -10.63% |
| 2012 FY | 8.08 Million USD | -58.33% |
| 2012 Q4 | 8.08 Million USD | 0.0% |
| 2011 FY | 19.4 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| America Great Health | 299.12 Thousand USD | -13474.411% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -607.897% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -176.318% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -30.082% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -1161.025% |
| Better Therapeutics, Inc. | 22.94 Million USD | -76.982% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -41.599% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -989.449% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -97.649% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -92.231% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 36.989% |
| Evolutionary Genomics, Inc. | 2.35 Million USD | -1625.149% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 42.807% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -55.331% |
| Innovation1 Biotech Inc. | 75.99 Thousand USD | -53332.553% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -233.676% |
| Molecular Templates, Inc. | 35.38 Million USD | -14.758% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -828.835% |
| NexImmune, Inc. | 8.59 Million USD | -372.484% |
| Orgenesis Inc. | 14.55 Million USD | -179.034% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -244.052% |
| Point of Care Nano-Technology, Inc. | 124.64 Thousand USD | -32477.04% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -614.826% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -10251.421% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 91.413% |
| Statera Biopharma, Inc. | 21.16 Million USD | -91.807% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -301.831% |
| Vaxxinity, Inc. | 44.35 Million USD | 8.45% |
| Vaccinex, Inc. | 3.63 Million USD | -1018.287% |
| Vicapsys Life Sciences, Inc. | 39.65 Thousand USD | -102293.08% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 28.376% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -7206.803% |